1
|
Leung SSY, Tsang HSL, Chan J, Kui OYH, Zeng P, Cheung YT, Cheng JW, Chan KCC, Yu M, Tang P, Brannan JD, Lam JKW, Chan HK, Li AM. Evaluation of bronchial hyperresponsiveness in asthmatic paediatric patients using mannitol challenge test - Impacts of body mass index. Ann Med 2025; 57:2468262. [PMID: 39977003 PMCID: PMC11843638 DOI: 10.1080/07853890.2025.2468262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 01/30/2025] [Accepted: 02/04/2025] [Indexed: 02/22/2025] Open
Abstract
BACKGROUND Increasing epidemiological studies reported that overweight/obese asthma patients had more frequent and severe symptoms and exacerbations, indicating their asthma management may not be sufficient. Airway hyperresponsiveness (AHR), a significant feature of asthma, was found to link with the body mass index (BMI) with mixed findings using the "direct" methacholine challenge test. The objective was to examine the association between BMI and asthma control, as reflected by the "indirect" AHR with the mannitol challenge test in a paediatric asthmatic population. METHODS A total of 80 subjects with physician-diagnosed asthma, aged 6-18 years were enrolled in this cross-sectional study. Patients were first asked to complete the Asthma Control Test (ACT) questionnaire to self-evaluate their disease status. A mannitol challenge test was then performed to assess their AHR severity. RESULTS Seventy-six patients (96%) rated their asthma as well-controlled with an ACT score ≥ 20, but 42 patients (53%) were tested positive in the mannitol challenge test with mild and moderate AHR. While patients with mild AHR had comparable lung functions to those without AHR, patients with moderate AHR showed slightly but significantly lower FEV1 and FEV1/FVC values. Although no significant difference in the BMI values was noted for patients with different levels of AHR, the trend of increasing BMI with age was steeper for patients with moderate AHR. CONCLUSION A high prevalence of AHR (>50%) was found in asthmatic children who self-evaluated with good asthma control. No significant influence of the BMI on the AHR severity could be demonstrated in this population with the "indirect" mannitol challenge test. Since only a small number of overweight/obese subjects were recruited in the present study, further verification of the results with a larger sample size of obese subjects is required.
Collapse
Affiliation(s)
- Sharon S. Y. Leung
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Helen S. L. Tsang
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Jasmine Chan
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Oliver Y. H. Kui
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Ping Zeng
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Yin Ting Cheung
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - James-Wesley Cheng
- Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Kate C. C. Chan
- Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Michelle Yu
- Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
| | - Patricia Tang
- Sydney Pharmacy School, University of Sydney, Sydney, Australia
| | - John D. Brannan
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - Jenny K. W. Lam
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK
| | - Hak-Kim Chan
- Sydney Pharmacy School, University of Sydney, Sydney, Australia
| | - Albert M. Li
- Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
| |
Collapse
|
2
|
Yang S, He X, Zhang R. Clinical efficacy of montelukast sodium combination therapy for cough variant asthma in children: A meta-analysis. Pediatr Pulmonol 2024; 59:1541-1551. [PMID: 38501316 DOI: 10.1002/ppul.26960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 02/26/2024] [Accepted: 03/01/2024] [Indexed: 03/20/2024]
Abstract
This meta-analysis aims to assess the clinical effectiveness of combination therapy with montelukast sodium for the treatment of cough variant asthma (CVA) in children, intending to provide clinical evidence and data to guide the selection of clinical therapy. A literature review was conducted using numerous databases, including China National Knowledge Infrastructure (CNKI), Wanfang database, Embase, PubMed, and Web of Science, from inception to December 2023. Trials meeting the criteria for the combined treatment of montelukast sodium for CVA in children were included. Stata 16.0 software was utilized for meta-analysis. The combined treatment group received montelukast sodium in addition to the control group, while the control group received budesonide, fluticasone propionate, salmeterol-fluticasone, or ketotifen alone. This investigation included 18 papers. All subjects were from the Chinese population. Compared to the control group, the combined treatment group demonstrated a higher effective rate (relative ratio [RR] = 1.23, 95% confidence interval [CI]: 1.18-1.29, p < .001), but no difference in the incidence of adverse reactions (RR = 0.65, 95% CI: 0.42-1.02, p = .060) after treatment. Moreover, the peak expiratory flow (PEF) (SMD = 1.69, 95% CI: 1.09-2.30, p < .001), forced vital capacity (FVC) (SMD = 1.67, 95% CI: 0.94-2.39, p < .001), forced expiratory volume in 1 s (FEV1) (SMD = 1.74, 95% CI: 1.09-2.40, p < .001), and FEV1/FVC (SMD = 1.84, 95% CI: 0.41-3.28, p = .012) were significantly higher in the combined treatment group than in the control group after treatment. Compared with the control group, the levels of tumor necrosis factor-α (SMD = -2.38, 95% CI: -3.22 to -1.55, p < .001), IL-4 (SMD = -2.65, 95% CI: -3.26 to -2.04, p < .001), and IgE (SMD = -2.98, 95% CI: -3.24 to -2.72, p < .001) were significantly lower in the combined treatment group after treatment. The combined use of montelukast sodium in the treatment of pediatric CVA in China is associated with a significant clinical effect, making it a reasonable therapeutic approach.
Collapse
Affiliation(s)
- Shihai Yang
- Department of Respiratory, Yuxi Children's Hospital, Yuxi, Yunnan, China
| | - Xia He
- Geriatrics Department, Ningxia Wuzhong People's Hospital, Wuzhong, Ningxia, China
| | - Rixia Zhang
- Pediatric Area II, The Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China
| |
Collapse
|
3
|
Tu H, Zhang Q. Assessment of Acupoint Therapy of Traditional Chinese Medicine on Cough Variant Asthma: A Meta-analysis. BIOMED RESEARCH INTERNATIONAL 2022; 2022:4168308. [PMID: 35941975 PMCID: PMC9356890 DOI: 10.1155/2022/4168308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 06/27/2022] [Accepted: 07/08/2022] [Indexed: 11/17/2022]
Abstract
Acupoint application has been used in China to treat various illnesses for ages. In cough variant asthma (CVA), the main clinical sign is episodic night cough. Acupoint application therapy of traditional Chinese medicine is an effective procedure to treat cough variant asthma. The current study is designed to systematically assess the effectiveness of acupoint application therapy in traditional medicine for patients with cough variant asthma. The comprehensive computer retrieval related to comparison between acupoint application and nonacupoint application therapy for cough variant asthma was carried out in various databases (n = 8) from database establishment until July 4, 2021. Both English and Chinese articles about original investigations in humans were searched. Two independent authors extracted the data, and disagreements were resolved by discussion. ReviewManager 5.3 software provided by Cochrane did a meta-analysis of selected randomized controlled trials (RCTs). Quality of experimentation and risk bias were analyzed by the Cochrane Handbook tool. A total of thirteen randomized controlled clinical articles along with 1237 patients were included in the study. Findings of meta-analysis showed that compared with nonacupoint application treatment, the total effective rate of acupoint application treatment is more effective (RD = 0.13, 95% CI (0.09, 0.17), Z = 6.70, P < 0.00001). Besides, acupoint application can improve patients' lung function, the lung function index FVC (mean difference = 0.55, 95% confidence interval (0.42, 0.68), Z = 8.40, P < 0.00001), FEV1 (MD = 0.35, 95% CI (0.23, 0.47), Z = 5.86, P < 0.00001), FEV1/FVC (%) (MD = 12.68, 95% CI (4.32, 21.03), Z = 2.97, P = 0.003), FEV1 (%) (MD = 8.63, 95% CI (8.01, 9.25), Z = 27.44, P < 0.00001), and PEF (day) (MD = 0.62, 95% CI (0.52, 0.71), Z = 12.40, P < 0.00001) of patients treated by acupoint application therapy were increased. Moreover, acupoint application might lower the level of immunoglobulin E (MD = -54.58, 95% CI (-63.54, -45.61), Z = 11.93, P < 0.00001) and EOS (MD = -0.21, 95% CI (-0.35, -0.06), Z = 2.77, P = 0.006). The LCQ (Leicester cough questionnaire) total score of CVA patients was also increased (MD = 2.30, 95% CI (1.55, 3.06), Z = 5.98, P < 0.00001). Acupoint application therapy is effective in controlling symptoms of CVA. It also has a positive effect in improving lung function and life quality of patients. It can reduce the eosinophil levels and peripheral blood IgE levels of patients as well.
Collapse
Affiliation(s)
- Hengjia Tu
- Nanshan School, Guangzhou Medical University, Guangzhou, 510000 Guangdong, China
| | - Qingling Zhang
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000 Guangdong, China
| |
Collapse
|
4
|
Woo H, Samra MS, Lim DH, Kim JH. Current Asthma Prevalence Using Methacholine Challenge Test in Korean Children from 2010 to 2014. J Korean Med Sci 2021; 36:e130. [PMID: 34002550 PMCID: PMC8129620 DOI: 10.3346/jkms.2021.36.e130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 04/07/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Most epidemiological studies depend on the subjects' response to asthma symptom questionnaires. Questionnaire-based study for childhood asthma prevalence may overestimate the true prevalence. The aim of this study was to investigate the prevalence of "Current asthma" using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and methacholine challenge test in Korean children. METHODS Our survey on allergic disease included 4,791 children (age 7-12 years) from 2010 to 2014 in Korean elementary schools. Bronchial hyperresponsiveness (BHR) was defined as provocative concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) ≤ 16 mg/mL. "Current asthma symptoms" was defined as positive response to "Wheezing, current," "Treatment, current," or "Exercise, current." "Current asthma" was defined when the subjects with "Current asthma symptoms" showed BHR on the methacholine challenge test or had less than 70% of predicted FEV1 value. RESULTS The prevalence of "Wheezing, ever," "Wheezing, current," "Diagnosis, ever," "Treatment, current," "Exercise, current," and "Current asthma symptoms" was 19.6%, 6.9%, 10.0%, 3.3%, 3.5%, and 9.6%, respectively, in our cross-sectional study of Korean elementary school students. The prevalence of BHR in elementary school students was 14.5%. The prevalence of BHR in children with "Wheezing, ever," "Wheezing, current," "Diagnosis, ever," "Treatment, current," and "Exercise, current" was 22.3%, 30.5%, 22.4%, 28.8%, and 29.9%, respectively. BHR was 26.1% in those with "Current asthma symptoms." The prevalence of "Current asthma" was 2.7%. CONCLUSIONS Our large-scale study provides 2.7% prevalence of current asthma in Korean elementary school children. Since approximately one third of the children who have "Current asthma symptoms" present BHR, both subjective and objective methods are required to accurately predict asthma in subjects with asthma symptoms.
Collapse
Affiliation(s)
- Hyeonjin Woo
- Department of Pediatrics, Inha University School of Medicine, Inha University Hospital, Incheon, Korea
| | - Mona Salem Samra
- Department of Pediatrics, Inha University School of Medicine, Inha University Hospital, Incheon, Korea
| | - Dae Hyun Lim
- Department of Pediatrics, Inha University School of Medicine, Inha University Hospital, Incheon, Korea
| | - Jeong Hee Kim
- Department of Pediatrics, Inha University School of Medicine, Inha University Hospital, Incheon, Korea.
| |
Collapse
|
5
|
Xiong J, Qi W, Yang H, Zou S, Kong J, Wang C, Zhou Y, Liang F. Acupuncture Treatment for Cough-Variant Asthma: A Meta-Analysis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2021; 2021:6694936. [PMID: 33868443 PMCID: PMC8034997 DOI: 10.1155/2021/6694936] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 03/17/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND In recent years, there have been many clinical reports on acupuncture treatment of cough-variant asthma, but no researcher has objectively analysed and evaluated the efficacy and safety of acupuncture treatment of cough-variant asthma from the perspective of evidence-based medicine. OBJECTIVE To systematically evaluate the clinical efficacy and safety of acupuncture in treating cough-variant asthma and to provide reference values for clinical decision-making. METHODS The comprehensive computer retrieval Chinese journal full-text database (CNKI), Chinese science and technology periodical database (VIP), ten thousand data knowledge service platform (WanFang Data), PubMed, Embase, and the Cochrane Library were used to collect literature for relevant randomized controlled trials (RCT) of acupuncture treatment of cough-variant asthma, as well as to retrieve papers and add reference retrieval after literature review, in accordance with the standard of literature filtering, data extraction, and quality evaluation. The data were meta-analysed using ReviewManager5.3 software recommended by Cochrane. RESULTS A total of 11 randomized controlled clinical studies were screened and included, comprising 929 patients. The results of the meta-analysis showed that, compared with the control group, acupuncture intervention on CVA could enhance the total clinical effectiveness rate, reduce the relapse rate of drug withdrawal, relieve symptoms of cough, phlegm, and diaphragmatic congestion, and improve lung function-related indicators and immune inflammation indicators. There were statistically significant differences in all efficacy evaluation criteria. CONCLUSION The clinical curative effect of acupuncture treatment for cough-variant asthma is precise and has certain advantages in relieving symptoms and reducing the recurrence rate. However, the low quality of the evaluation in the RCT research literature is a problem, and more high-quality clinical randomized controlled trials are needed to further verify the comprehensive clinical efficacy and safety of this treatment. Registration number: PROSPERO (no. CRD42020155244) (https://www.crd.york.ac.uk/prospero/).
Collapse
Affiliation(s)
- Jian Xiong
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| | - WenChuan Qi
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| | - Han Yang
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| | - SiTing Zou
- Guangxi University of Traditional Chinese Medicine, Nanning 5300013, Guangxi, China
| | - Jing Kong
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| | - ChengLong Wang
- The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 168600, China
| | - YuanFang Zhou
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| | - FanRong Liang
- Chengdu University of Traditional Chinese Medicine, Chengdu 6100752, Sichuan, China
| |
Collapse
|
6
|
Stöwhas M, Lippert H. [Impact of COVID-19 Outbreak on Emergency Department Admissions in a Specialized Hospital]. DAS GESUNDHEITSWESEN 2021; 83:265-273. [PMID: 33733450 PMCID: PMC8043597 DOI: 10.1055/a-1384-0508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Mathias Stöwhas
- Medizincontrolling, KMG Kliniken SE, Bad Wilsnack, Deutschland.,Fakultät Gesundheitswissenschaften , MSB Medical School Berlin GmbH, Berlin, Deutschland
| | - Hans Lippert
- Klinik für Allgemein-, Viszeral-, Gefäß- und Transplantationschirurgie, Otto von Guericke Universitat Magdeburg, Magdeburg, Deutschland
| |
Collapse
|
7
|
Li S, Ma X, Xie J, Yan X, Sun W. MicroRNA-206, IL-4, IL-13, and INF-γ levels in lung tissue and plasma are increased by the stimulation of particulate matter with a diameter of ≤2.5μm, and are associated with the poor prognosis of asthma induced pulmonary arterial hypertension patients. Clin Exp Hypertens 2020; 43:181-188. [PMID: 33086901 DOI: 10.1080/10641963.2020.1836192] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND This study aimed to explore the prognostic value of particulate matter with a diameter of ≤2.5 μm (PM2.5)-related microRNA-206 combined with interleukin (IL)-4, IL-13 and interferon-γ (INF-γ) in asthma induced pulmonary arterial hypertension (PAH). METHODS Fifty SPF BALB/c mice were divided into 5 groups: control group, asthma + PAH group, low-toxic asthma + PAH group, moderately-exposed asthma + PAH group, highly-exposed asthma + PAH group. Differences of microRNA-206, IL-4, IL-13, and INF-γ expression in lung tissue and plasma were detected. A total of 98 patients with asthma induced PAH and 98 healthy persons were collected. Patients were followed up for 12 months. RESULTS Based on microarray analyses, we found that microRNA-206 may be involved in asthma induced PAH stimulated by PM2.5. Compared with healthy people, plasma microRNA-206, IL-4, IL-13, and INF-γ levels in asthma induced PAH patients were significantly higher (P< .05). Compared with survivors, plasma microRNA-206, IL-4, IL-13, and INF-γ levels in non-survivors were significantly higher (P< .05). Survival analyses showed that compared with low microRNA-206, low IL-4, low IL-13 and low INF-γ groups, survival rate of patients in high microRNA-206 (χ2 = 4.864, P= .013), high IL-4 (χ2 = 3.774, P= .038), high IL-13 (χ2 = 8.375, P< .001) and high INF-γ groups (χ2 = 9.007, P< .001) were significantly reduced. Established prognostic evaluation model was built and the estimated probability was 0.473. Compared with estimated probability ≤ 0.473, survival rate of patients in estimated probability> 0.473 was significantly reduced (χ2 = 17.377, P< .001). CONCLUSION Current model combining plasma microRNA-206, IL-4, IL-13, and INF-γ has potential significance for prognosis of asthma induced PAH.
Collapse
Affiliation(s)
- Shaohua Li
- Department of Respiratory and Critical Care Medical, The Second Hospital of Hebei Medical University , Shijiazhuang, Hebei, China.,Department of Respiratory and Critical Care Medical, The First Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
| | - Xiaoning Ma
- Intensive Care Unit of Shijiazhuang First Hospital, People's Hospital in Shijiazhuang , Shijiazhuang, Hebei, China
| | - Jianli Xie
- Rheumatology and Immunology Department, The Third Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
| | - Xixin Yan
- Department of Respiratory and Critical Care Medical, The Second Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
| | - Wuzhuang Sun
- Department of Respiratory and Critical Care Medical, The First Hospital of Hebei Medical University , Shijiazhuang, Hebei, China
| |
Collapse
|
8
|
Shakya AK, Lee CH, Gill HS. Microneedle-Mediated Allergen-Specific Immunotherapy for the Treatment of Airway Allergy in Mice. Mol Pharm 2020; 17:3033-3042. [DOI: 10.1021/acs.molpharmaceut.0c00447] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Akhilesh Kumar Shakya
- Department of Chemical Engineering, Texas Tech University, Lubbock, Texas 79409, United States
| | - Chang Hyun Lee
- Department of Chemical Engineering, Texas Tech University, Lubbock, Texas 79409, United States
| | - Harvinder Singh Gill
- Department of Chemical Engineering, Texas Tech University, Lubbock, Texas 79409, United States
| |
Collapse
|
9
|
Veettil ST, Alnuaimi ASA. Epidemiology and utilization of primary health care services in Qatar by asthmatic children 5-12 years old: secondary data analysis 2016-2017. Asthma Res Pract 2019; 5:3. [PMID: 31452904 PMCID: PMC6700832 DOI: 10.1186/s40733-019-0050-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Accepted: 08/09/2019] [Indexed: 11/10/2022] Open
Abstract
Background Childhood asthma is a growing clinical problem and a burden on the health care system due to repetitive visits to children's emergency departments and frequent hospital admissions where it is poorly controlled. Due to lack of reliable baseline information on its prevalence among children in Qatar and the extent of their utilization of primary health care services, we sought to analyse electronic medical records data for children aged 5-12 years. Objectives Our primary objective was to establish point prevalence over the period 2016-2017. Furthermore, we wanted to assess the frequency and pattern of use of the primary care services including any demographic and seasonal variations, the types of clinical encounter and treatment received. Methods A cross sectional study on 54,704 clinical encounters of electronic health records for children aged 5 to 12 years in which a diagnosis of Asthma was tagged during a two years period. Results The prevalence rate of Asthma out of total registered clients in the specified pediatric age group (196,557) is 6.1%. The rate was highest (10.2%) in youngest age group (5-6 years old) and lowest (4.1%) in teenagers (10-12 years old). An obvious peak of clinical encounters of Asthma cases was observed in Oct and Nov. The work load in PHCC clinics for Asthma clinical encounters is increased by more than 50% compared to the average monthly count of 4556.Moreover, the rate was higher in males (7.6%) compared to females (4.6%). The most frequently prescribed medication group was antihistamine (57.8%) followed by adrenergic bronchodilators (33.9%). Conclusions Asthma constitutes an important part (8.5%) of the total primary care clinic work load among children aged 5-12 years in Qatar. A guideline need to encourage physician to use preventive Asthma strategies including steroid medications to provide continuity of care for Asthma cases.
Collapse
Affiliation(s)
- Shajitha Thekke Veettil
- 1Clinical Research Department, Primary Health Care Corporation, Head Quarters Tower 1, 8th Floor, PO Box: 26555, Doha, Qatar.,Directorate of Clinical Affairs, Al Salata, Al Meena Street, Doha, Qatar
| | - Ahmed Sameer AbdulHameed Alnuaimi
- 1Clinical Research Department, Primary Health Care Corporation, Head Quarters Tower 1, 8th Floor, PO Box: 26555, Doha, Qatar.,Directorate of Clinical Affairs, Al Salata, Al Meena Street, Doha, Qatar
| |
Collapse
|